Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease;Documento de Consenso de Expertos sobre el uso de inhibidores de la enzima de conversión de la angiotensina en la enfermedad cardiovascular

Revista Espanola de Cardiologia

Volumn 57, Issue 12, 2004, Pages 1213-1232

  López Sendón, José ^a   Swedberg, Karl ^b   McMurray, John ^b   Tamargo, Juan ^b   Maggioni, Aldo P ^b   Dargie, Henry ^b   Tendera, Michal ^b   Waagstein, Finn ^b   Kjekshus, Jan ^b   Lechat, Philippe ^b   Torp Pedersen, Christian ^b  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTACID AGENT; BENAZEPRIL; CANDESARTAN; CAPTOPRIL; CILAZAPRIL; CYCLOSPORIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; HYDRALAZINE; ISOSORBIDE DINITRATE; LISINOPRIL; LOSARTAN; NONSTEROID ANTIINFLAMMATORY AGENT; OMAPATRILAT; PERINDOPRIL; QUINAPRIL; RAMIPRIL; SALICYLIC ACID; SPIRAPRIL; SPIRONOLACTONE; TRANDOLAPRIL; UNINDEXED DRUG; VALSARTAN; ZOFENOPRIL;

ANGIONEUROTIC EDEMA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLIC; CONSENSUS DEVELOPMENT; DIARRHEA; DISEASE EXACERBATION; DOSE CALCULATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG COMPETITION; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG MECHANISM; DRUG TOLERABILITY; DRUG TRANSFORMATION; EVIDENCE BASED MEDICINE; FIBRINOLYSIS; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE FAILURE; HEMODYNAMICS; HORMONE ACTION; HUMAN; HYPERPHOSPHATEMIA; HYPERTENSION; HYPOTENSION; KIDNEY FAILURE; KIDNEY FUNCTION; LUNG HYPOPLASIA; META ANALYSIS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OLIGOHYDRAMNIOS; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STROKE; TERATOGENICITY; VOMITING;

EID: 19944431768     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13069868     Document Type: Review

References (113)

1. Williams GH. Converting-enzyme inhibitors in the treatment of hypertension. N Engl J Med 1988;319:1517-25.
2. Kostis JB. Angiotensin-converting enzyme inhibitors. Emerging differences and new compounds. Am J Hypertens 1989;2:57-64.
3. Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation 1998;97:1411-20.
4. Jackson EK. Renin and angiotensin. En: Hardman JG, Limbird LE, editors. The pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill, 2001; p. 809-41.
5. Hoyer J, Schulte KL, Lenz T. Clinical pharmacokinetics of angioten-sin converting enzyme (AC) inhibitors in renal failure. Clin Pharmacokinet 1993;24:230-54.
6. Lonn EM, Yusuf S, Jha P, et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994;90:2056-69.
7. Zimmerman BG, Sybertz EJ, et al. Interaction between sympathetic and renin-angiotensin system. J Hypertens 1984;2:581-92.
8. Hornig H, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997;95:1115-8.
9. Linz W, Wohlfart P, Schoelkens BA, et al. Interactions among ACE, kinins and NO. Cardiovasc Res 1999;43:549-61.
10. Dzau VA. The relevance of tissue angiotensin-converting-enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol 2001;88:1-20.
11. Giannettasio C, Grassi G, Seravalle G, et al. Investigation of reflexes from volume and baroreceptors during converting-enzyme inhibition in humans. Am Heart J 1989; 117:740-5.
12. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: A meta-analysis of randomized double-blind studies. JAMA 1996;275:1507-13.
13. Thadei S, Virdis A, Ghiadoni L, et al. Effects of angiotensin converting enzyme inhibition on endothelium-dependent vasodilation in patients with essential hypertension. J Hypertens 1998;16:447-56.
14. Hornig B, Landmesser U, Kohler C, et al. Comparative effect of ACE inhibition and angiotensin H type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation 2001;103:799-805.
15. Hornig B, Arakawa N, Drexler H. Effect of ACE inhibition on endothelial dysfunction in patients with chronic heart failure. Eur Heart J 1998; 19(Suppl G):G48-53.
16. Francis GS, Benedict C, Johnstone DE, et al, for the SOLVD Investigators. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the studies of left ventricular dysfunction (SOLVD). Circulation 1990;82:1724-9.
17. Swedberg K, Eneroth P, Kjekshus J, et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990;82:1730-6.
18. Swedberg K. Importance of neuroendocrine activation in chronic heart failure. Impact on treatment strategies. Eur J Heart Fail 2000;2:229-33.
19. Husain A. The chymase-angiotensin system in humans. J Hypertens 1993;11:1155-9.
20. Lee AF, MacFadyen RJ, Struthers AD. Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study. Eur J Heart Fail 1999;1:401-6.
21. Boon WC, McDougall JG, Coghlan JP. Hypothesis: aldosterone is synthesized by an alternative pathway during severe sodium depletion. «A new wine in an old bottle». Clin Exp Pharmacol Physiol 1998;25:369-78.
22. + stimulated aldosterone secretion. Mol Cell Endocrinol 2001;175:157-71.
23. Paul M, Ganten D. The molecular basis of cardiovascular hypertrophy: the role of the renin-angiotensin system. J Cardiovasc Pharmacol 1992; 19(Suppl 5): S51-8.
24. Schiffrin E, Deng L. Comparison of effects of angiotensin I-converting enzyme inhibition and β-blockade for 2 years on function of small arteries from hypertensive patients. Hypertension 1995; 25:699-703.
25. Matsuda H, Hayashi K, Arakawa K. Zonal heterogeneity in action of angiotensin-converting enzyme inhibitor on renal microcirculation: role of intrarenal bradykinin. J Am Soc Nephrol 1999;10:2272-82.
26. Keane WF, Shapiro BE. Renal protective effects of angiotensin-converting enzyme inhibition. Am J Cardiol 1990;65:491-531.
27. Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies and non-nephrotic proteinuria. Lancet 1999;354:359-64.
28. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62.
29. Pitt B. Potential role of angiotensin converting enzyme inhibitors in the treatment of atherosclerosis. Eur Heart J 1995;16:49-54.
30. Schoelkens BA, Landgraf W. ACE inhibition and atherosclerosis. Can J Physiol Phatmacol 2002;80:354-9.
31. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-77.
32. Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fraction. Lancet 1993;340:1173-8.
33. Teo KK, Yusuf S, Pfeffer M, et al, for the ACE Inhibitors Collaborative Group. Effects of long-term treatment with angiotensin-converting enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet 2002;360:1037-43.
34. The Heart Outcomes Prevention Evaluation Study Investigators (HOPE). Effects of angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
35. Lonn EM, Yusuf S, Dzavik V, et al. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001;103:919-25.
36. Vaughan D. The renin-angiotensin system and fibrinolysis. Am J Cardiol 1997;79(Suppl 5):12-6.
37. DiBianco R. Adverse reactions with angiotensin converting enzyme inhibitors. Med Toxicol 1986;1:122-41.
38. Visser LE, Stricker BH, Van der Velden J, et al. Angiotensin converting enzyme inhibitor associated cough: a population-based case-control study. J Clin Epidemiol 1995;48:851-7.
39. Wood R. Bronchospasm and cough as adverse reactions to the ACE inhibitors captopril, enalapril and lisinopril. A controlled retrospective cohort study. Br J Clin Pharmacol 1995;39:265-70.
40. Charlon V, Dollow S, Fidel J, et al. Reproducibility of angiotensin converting enzyme inhibitor induced cough: a double-blind randomised study. Br J Clin Pharmacol 1995;39:125-9.
41. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. Ann Intern Med 1992; 117:234-42.
42. Ahuja TS, Freeman D, Mahnken JD, et al. Predictors of the development of hyperkalemia in patients using angiotensin-converting enzyme inhibitors. Am J Nephrol 2000;20:268-72.
43. The RALES investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure. (The randomized aldactone evaluation study: RALES). Am J Cardiol 1996;78:902-7.
44. Wynckel A, Ebikili B, Melin JP, et al. Long-term follow-up of acute renal failure caused by angiotensin converting enzyme inhibitors. Am J Hypertens 1998;11:1080-6.
45. Brown N, Ray W, Snowden M, et al. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther 1996;60:8-13.
46. Sedman AB, Kershaw DB, Bunchman TE. Recognition and management of angiotensin converting enzyme inhibitors. Pediatr Nephrol 1995;9:382-5.
47. Brent RL, Beckman DA. Angiotensin-converting enzyme inhibitors, an embryopathic class of drugs with unique properties: information for clinical theratology counselors. Teratology 1991;43:543-6.
48. Oakley C, Child A, Iung B, Prebitero P, Tornos P, for the Task force on the management of cardiovascular diseases during pregnancy of the European Society of Cardiology. Expert consensus document on management of cardiovascular diseases during pregnancy. Eur Heart J 2003;24:761-81.
49. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, et al, for the Task force on hypertrophic cardiomyopathy. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. Eur Heart J 2003;25:1965-91.
50. Remme WJ, Swedberg K, et al for the task force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-60.
51. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure) ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult 2002. Disponible en: http://www.acc.org
52. Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status. A meta-analysis of major clinical trials. J Am Coll Cardiol 2003;41:1529-38.
53. Flather M, Yusuf S, Køber L, Pfeffer M, Hall A, Murria G, et al, for the ACE-Inhibitor Myocardial Infarction Collaborative Group. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000;355:1575-781.
54. The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987; 316:1429-35.
55. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
56. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-10.
57. Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy. Lancet 1993;342:821-8.
58. Narang R, Swedberg K, Cleland JG. What is the ideal study design for evaluation of treatment for heart failure? Insights from trials assessing the effect of ACE inhibitors on exercise capacity. Eur Heart J 1996;17:120-34.
59. Northridge DB, Rose E, Raftery ED, et al. A multicentre, double-blind, placebo-controlled trial of quinapril in mild, chronic heart failure. Eur Heart J 1993;14:403-9.
60. Gundersen T, Swedberg K, Amtorp O, et al. Absence of effect on exercise capacity of 12-weeks treatment with ramipril in patients with moderate congestive heart failure. Ramipril Study Group. Eur Heart J 1994; 15:1659-65.
61. Gundersen T, Wiklund I, Swedberg K. Effects of 12 weeks of ramipril treatment on the quality of life in patients with moderate congestive heart failure: results of a placebo-controlled trial. Raipril Study Group: Cardiovasc Drugs Ther (United States), Aug 1995;9:589-94.
62. Packer M, Poole-Wilson PA, Armstrong PW, et al, on behalf of the ATLAS study group. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999;100:2312-8.
63. The NETWORK investigators. Clinical outcome with enalapril in symptomatic chronic heart failure, a dose comparison. Eur Heart J 1998;19:481-9.
64. MacMurray J, Cohen-Solal A, Dietz R, et al. Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: putting guidelines into practice. Eur J Heart Failure 2001;3:495-502.
65. Pitt B, A Poole-Wilson PA, Segl R, on behalf of the ELITE II investigators. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial -the Losartan Heart Failure Survival Study ELITE II. Lancet 2000:355:1582-7.
66. Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee for the OPTIMAAL Study Group Effects of losartan and captopril on mortality and morbidity high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002;360;752-60.
67. Pfeffer MA, McMurray JJV, Velasquez EJ, et al, for the Valsartan in Acute Myocardial Infarction Trial Investigators Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both. N Engl J Med 2003;349:1893-906.
68. McMurray JJV, Östergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362: 767-71.
69. Packer M, Califf RM, Konstam MA, for the OVERTURE Study Group. Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart Failure, The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002;920:106-26.
70. The SOLVD Investigators. Effect of enalapril on mortality and development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327:685-91.
71. Jong P, Yusuf S, Rousseau MF, et al. Effect of nealapril on 12 year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 2003;361:1843-8.
72. Vermes E, Ducharme A, Bourassa MG, et al. Enalapril reduces the incidence of diabetes in patients with chronic heart failure. Insight from the studies of left ventricular dysfunction (SOLVD). Circulation 2003;107:1291-6.
73. Kober L, Torp-Pedersen C, Carlsen JE, et al, for the trandolapril cardiac evaluation (TRACE) study group: a clinical trial of the angiotensin converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;33:1670-6.
74. Torp-Pedersen C, Kober L. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. Lancet 1999;354:9-12.
75. Philbin EF, Rocco TA, Lindenmuth NW, et al. Systolic versus diastolic heart failure in community practice: clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors. Am J Med 2000;109:605-13.
76. Cleland JG. ACE inhibitors for «diastolic» heart failure? Reasons not to jump to premature conclusions about the efficacy of ACE inhibitors among older patients with heart failure. Eur J Heart Fail 2001;3:637-9.
77. Effects of cardiac versus circulatory angiotensin-converting enzyme inhibition on left ventricular diastolic function and coronary blood flow in hypertrophic obstructive cardiomyopathy. Circulation 1998;97:1342-7.
78. Devereux RB, Palmieri V, Sharpe N, et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial. Circulation 2001; 104:1248-54.
79. Beltman F, Heesen W, Smit A, et al. Two-year follow-up study to evaluate the reduction of left ventricular mass and diastolic function in mild to moderate diastolic hypertensive patients. J Hypertens 1998;16:S15-9.
80. Yusuf S, Pfeffer MA, Swedberg K, Granger KB, Held P, McMurray JJV, et al, for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM Preserved Trial. Lancet 2003;362:777-81.
81. Van de Werf, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KAA, et al, for the task force of the management of acute myocardial infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with ST segment elevation. Eur Heart J 2003;24:28-66.
82. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction) ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction American College of Cardiology; September 1999. Disponible en: www.acc.org
83. Gottlieb S, Leor J, Shotan A, Harpaz D, Boyko V, Rott D, et al. Comparison of effectiveness of angiotensin-converting enzyme inhibitors after acute myocardial infarction in diabetic versus nondiabetic patients. Am J Cardiol 2003;92:1020-5.
84. Swedberg K, Held P, Kjekshus J, et al. Effects of early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSESSUS II). N Engl J Med 1992;327:678-84.
85. Fourth International Study of Infarct Survival Collaborative Group. ISIS-IV: a randomised factorial trial assessing early oral captopril. Oral mononitrate and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-85.
86. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6 week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-22.
87. Chinese Cardiac Study Collaborative group. Oral captopril versus placebo among 13634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study. Lancet 1995;345:686-7.
88. Ambrosioni E, Borghi C, Magnani B, for the survival of myocardial infarction long term evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting-enzyme inhibitor on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995;332:80-5.
89. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100 000 patients in randomized trials. Circulation 1998;97:2202-12.
90. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, doubleblind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8.
91. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K, et al, for the Second Joint Task Force of European and other Societies on Coronary Prevention: European Society of Cardiology, European Atherosclerosis Society, European Society of Hypertension, International Society of Behavioural Medicine, European Society of General Practice/Family Medicine, European Network. Prevention of coronary heart disease in clinical practice. Eur Heart J 1998; 19:1434-503.
92. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. JAMA 2003;289: 2560-72.
93. De Backer G, Ambrosioni E, Borch-Johnses K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003;24:1601-10.
94. Hansson L, Lindholm L, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751-6.
95. Estacio R, Jeffers B, Hiatt W, et al. The effect of nisoldipine as compared with enalapril on outcomes in patients with non-insulin dependant diabetes and hypertension. N Engl J Med 1998; 338:645-52.
96. Hansson L, Lindholm L, Niskanen L, et al. Effect of angiotensin converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611-6.
97. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998;317: 713-20.
98. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.
99. Collaborative Group Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358: 1033-41.
100. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000;355:1955-64.
101. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001;358: 1305-15.
102. Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003;348:583-92.
103. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowefing Treatment to Prevent Heart Attack Trial. JAMA 2002;288:2981-97.
104. MacMahon S, Sharpe N, Gamble G, et al. Randomised, placebo controlled trial of the angiotensin converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive vascular disease. J Am Coll Cardiol 2000;36:438-43.
105. Cashin-Hemphill L, Holmvang G, Chan R, et al. Angiotensin converting enzyme inhibition as antiatherosclerotic therapy: no answer yet. Am J Cardiol 1999;83:43-7.
106. Teo K, Burton J, Buller C, et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the Simvastatin/enalapril Coronary Atherosclerosis Trial (SCAT). Circulation 2000;102:1748-54.
107. Arnold JMO, Yusuf S, Young J, et al, on behalf of the HOPE Investigators. Prevention of heart failure in patients in the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation 2003; 107:1284-90.
108. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9.
109. Bosch J, Yusuf S, Pogue J, et al. Use of ramipril in preventing stroke: double blind randomised trial. BMJ 2002;324;699-702.
110. Sleight P, Yusuf S, Pogue J, et al. Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet 2001;358:2130-1.
111. Yusuf S. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol 2002;89:18A-25A.
112. Priori SG, Aliot E, Blomström-Lundqvist C, et al, for the Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J 2001;22:1374-450.
113. Priori SG, Aliot E, Blomström-Lundqvist C, et al, for the Task Force on Sudden Cardiac Death of the European Society of Cardiology. Update on the guidelines for sudden cardiac death of the European Society of Cardiology. Eur Heart J 2003;24:13-5.